Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075829 · ClinicalTrials.gov registry record · Phase 3
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Phase 3 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 3
- Development phase
- 710
- Enrollment target
NCT00075829: Completed Phase 3 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00075829 is a Phase 3 study that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 710 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00075829, a Phase 3 study, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 710 participants
- Enrollment target
Study Summary
The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant. Study subjects will be biologically assigned to the appropriate arm depending on the availability of an HLA-matched sibling. There is a nested randomized phase III trial of observation versus maintenance therapy following the second autologous transplant for patients on the tandem autologous transplant arm.
Primary Outcome
Patients are considered a failure for this endpoint if they die or if they progress or relapse.
Interventions
- DRUG Dexamethasone
- DRUG Thalidomide
- PROCEDURE One Autologous Transplant
- PROCEDURE Non-Myeloablative Allogeneic Transplant
- PROCEDURE Second Autologous Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 710 participants |
| Start Date | 2003-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
What the finished NCT00075829 record still lists
NCT00075829 is an interventional study that assigns participants to a tested intervention. The registered 710 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Dexamethasone is the first listed.
NCT00075829 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00075829 about?
NCT00075829 is a clinical study titled "Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)". The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant. Study subjects will be biologically assigned to the appropriate arm depending...
What is the current status of trial NCT00075829?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 710 participants. The study started on 2003-12. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00075829?
The interventions under investigation include: Dexamethasone (DRUG), Thalidomide (DRUG), One Autologous Transplant (PROCEDURE), Non-Myeloablative Allogeneic Transplant (PROCEDURE), Second Autologous Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00075829?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00075829's enrollment target sits among peer trials
710 502nd of 2000 higher than 1,496 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia